|
|
|
FDA Panel Backs Glaxo Cancer Drug
An FDA advisory panel is recommending approval of an experimental drug that can benefit kidney cancer patients.
|
|
0 Comments
Font Size:
GAITHERSBURG, Md. (October 5, 2009)--Federal health advisers say an experimental kidney cancer drug from GlaxoSmithKline can benefit patients by slowing the disease, despite some risk of liver damage.
The U.S. Food and Drug Administration's cancer drug panel voted unanimously in favor of Glaxo's pazopanib pills for advanced kidney cancer, a rare but deadly form of the disease.
The agency is not required to follow the group's advice, although it usually does.
Studies by the British drug maker showed higher rates of liver damage among patients taking the drug, compared with patients taking a placebo, but panelists said the risks were not significantly worse than those with similar cancer drugs.
More Stories
KWTX.com Features
 |
Double
Dollar Deals Half Price Deals at Central Texas restaurants and businesses. A new deal every Thursday at 7:00am. |
 |
Boss
of the Month Who is Central Texas’ best boss? Nominate your supervisor for Boss of the Month! |
 |
Golden
Apple Your chance to nominate an outstanding teacher. Find out how they are making a difference in classrooms. |
 |
Emily Wants to Know Emily Matthews' inquisitive look at life in Central Texas. |
 |
Army Way Learn all about the symbols, traditions, and customs of the US Army. |
For Your Health
